The use of human fetal tissue and embryonic stem cells in medicine and research has led to many advances through an improved understanding of congenital abnormalities and human disease development. This research has enabled the use of stem cells lines (cell cultures that can be grown indefinitely in the laboratory) and humanised mice to provide insights into human diseases. Therefore, proponents of such research efforts watched in dismay when on June 5, 2019, the Trump administration imposed restrictions on the government funding for research with fetal tissue from elective abortions, which will severely curtail research efforts, including crucial ongoing projects into vaccines and HIV therapies.
The use of human fetal tissue has been strongly opposed by anti-abortion groups and the conservative political base who have supported President Trump. Although the funding restriction applied only to fetal tissue, there was concern that embryonic stem cell research might also be halted when President Trump took office, as occurred in 2001 when President Bush imposed a ban on federal funding for research on newly created human embryonic stem cell lines; thankfully, to date, no such limitations have been imposed. Opponents of using embryonic stem cells and fetal tissue argue that there are alternative animal models, umbilical cord stem cells, or adult stem cells that have been used with some success in certain areas of research. Several studies are using mesenchymal stem cells (MSC), which are found in the bone marrow, and exploring their effect on immune responses in the body to reduce inflammation associated with disease. The START study investigated administration of these cells to patients with moderateto-severe acute respiratory distress syndrome (ARDS) and found they were safe, but 28-day mortality did not differ from the placebo group, which might be partly explained by issues with cell viability. Another study, presented at the 2019 American Thoracic Society Conference, in May, was the MUST-ARDS trial that used allogeneic bone marrow-derived multipotent adult progenitor cells in patients with ARDS; the study met its safety endpoints and, although it wasn't powered for secondary outcomes of mortality, intensive care unit, and ventilator-free days, numerical improvements were also noted in these endpoints.
Stem cell therapy research in lung disease is still at early stages, but the research output is increasing and the area is a promising one. However, there are limits to the use of MSC and other adult multipotent stem cells, because substantial numbers are required for therapeutic effects. The cells also have a shorter replicative lifespan and can only make a restricted number of specialised cell types that are specific for their organ of origin. Fetal tissue, by contrast, provides cell lines that grow rapidly, are able to easily differentiate into multiple cell types, and are less likely to be rejected by the body. In the future, fetal tissue might be replaced in certain areas of research with the use of induced pluripotent stem cells and organoids, which are human-cell cultures that can be crafted to replicate an organ. However, in areas such as fetal development, a suitable replacement to fetal tissue is unlikely to be found. Although research into fetal tissue alternatives is worthwhile, it will take time and until then, the use of fetal tissue is essential so that research efforts, which are crucial for the development of new therapeutic treatments in often difficult-to-treat lung diseases, are not severely hampered. And those in the field need to ensure their voices are heard.
Indeed, the American Thoracic Society released a statement the day after the Trump administration announce ment saying that "Scientific research with fetal tissue is vital for the development of new treatments for many deadly diseases and conditions, such as cystic fibrosis and acute lung injury. There are no alternative research models that can replace all fetal tissue research". Fetal tissue has been a key part of the development of multiple vaccines, treatments for cystic fibrosis, and ongoing research into cancer immunotherapy.
The major objection to fetal tissue research is that the source of the fetal tissue is mainly from elective abortions. However, there is no suggestion that the number of abortions will decrease as a result of removing funding for fetal tissue research. Abortion is still legal in all 50 states in the USA and fetal tissue would otherwise be discarded. Fetal tissue research, in fact, holds the potential to save lives through the development of new treatments and vaccines. Politicising scientific research in this way means denying hope to millions of patients with life-limiting diseases. ■ The Lancet Respiratory Medicine For the ATS press release see http://www.thoracic.org/about/ newsroom/press-releases/ journal/2019/ats-concerned-bytrump-administration-actionhalting-nih-fetal-tissueintramural-research.php
